These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38140993)

  • 21. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry.
    Rodriguez F; Cannon CP; Steg PG; Kumbhani DJ; Goto S; Smith SC; Eagle KA; Ohman EM; Umez-Eronini AA; Hoffman E; Bhatt DL;
    Clin Cardiol; 2013 Dec; 36(12):721-7. PubMed ID: 24166484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill.
    Sanz G; Fuster V
    Mt Sinai J Med; 2012; 79(6):683-8. PubMed ID: 23239207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population.
    Sanz G; Fuster V
    Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):101-10. PubMed ID: 19104519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
    Roy A; Naik N; Srinath Reddy K
    Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
    Ostovaneh MR; Poustchi H; Hemming K; Marjani H; Pourshams A; Nateghi A; Majed M; Navabakhsh B; Khoshnia M; Jaafari E; Mohammadifard N; Malekzadeh F; Merat S; Sadeghi M; Naemi M; Etemadi A; Thomas GN; Sarrafzadegan N; Cheng KK; Marshall T; Malekzadeh R
    Eur J Prev Cardiol; 2015 Dec; 22(12):1609-17. PubMed ID: 25230980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease.
    Wood F; Salam A; Singh K; Day S; Jan S; Prabhakaran D; Rodgers A; Patel A; Thom S; Ward H
    BMJ Open; 2015 Sep; 5(9):e008018. PubMed ID: 26423850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.
    Bramlage P; Sims H; Minguet J; Ferrero C
    Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Polypill: From Promise to Pragmatism.
    Huffman MD
    PLoS Med; 2015 Aug; 12(8):e1001862. PubMed ID: 26263422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The polypill strategy in cardiovascular disease prevention: It's time for its implementation.
    Di Fusco SA; Aquilani S; Spinelli A; Alonzo A; Matteucci A; Castello L; Imperoli G; Colivicchi F
    Prog Cardiovasc Dis; 2023; 79():37-40. PubMed ID: 36931543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polypill Trials for Stroke Prevention-Main Results, Critical Appraisal, and Implications for US Population.
    Ibraheem M; Goldstein LB
    Curr Neurol Neurosci Rep; 2020 Apr; 20(5):10. PubMed ID: 32296941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Could the polypill improve adherence? The patient perspective.
    Bryant L; Martini N; Chan J; Chang L; Marmoush A; Robinson B; Yu K; Wong M
    J Prim Health Care; 2013 Mar; 5(1):28-35. PubMed ID: 23457692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adherence to cardiovascular medication: a review of systematic reviews.
    Leslie KH; McCowan C; Pell JP
    J Public Health (Oxf); 2019 Mar; 41(1):e84-e94. PubMed ID: 29850883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
    Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
    Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medication adherence: a call for action.
    Bosworth HB; Granger BB; Mendys P; Brindis R; Burkholder R; Czajkowski SM; Daniel JG; Ekman I; Ho M; Johnson M; Kimmel SE; Liu LZ; Musaus J; Shrank WH; Whalley Buono E; Weiss K; Granger CB
    Am Heart J; 2011 Sep; 162(3):412-24. PubMed ID: 21884856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating patients' satisfaction and preferences with a secondary prevention cardiovascular polypill: the Aurora Study.
    Cosin-Sales J; Murcia-Zaragoza JM; Pereyra-Rico HO; la Guía-Galipienso F; Hermans K; Rubio G
    J Comp Eff Res; 2021 Sep; 10(13):975-985. PubMed ID: 34196593
    [No Abstract]   [Full Text] [Related]  

  • 36. [Is the "polypill" in cardiovascular prevention an option].
    Flatz A; Renard D; von Elm E
    Praxis (Bern 1994); 2015 Mar; 104(6):305-6. PubMed ID: 25758972
    [No Abstract]   [Full Text] [Related]  

  • 37. A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension.
    Coca A; Kreutz R; Manolis AJ; Mancia G
    J Hypertens; 2020 Oct; 38(10):1890-1898. PubMed ID: 32890261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medication adherence, biological and lifestyle risk factors in patients with myocardial infarction: a ten-year follow-up on socially differentiated cardiac rehabilitation.
    Hald K; Larsen FB; Nielsen KM; Meillier LK; Johansen MB; Larsen ML; Christensen B; Nielsen CV
    Scand J Prim Health Care; 2019 Jun; 37(2):182-190. PubMed ID: 31122102
    [No Abstract]   [Full Text] [Related]  

  • 39. Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.
    López-Jaramillo P; González-Gómez S; Zarate-Bernal D; Serrano A; Atuesta L; Clausen C; Castro-Valencia C; Camacho-Lopez P; Otero J
    Ther Adv Cardiovasc Dis; 2018 Jun; 12(6):169-174. PubMed ID: 29546816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
    Kones R
    Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.